Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | MEN1 | O00255 | 8/20 | 0.42 |
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.40 |
| ▸ | TP53 | P04637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6655343 | 0.97 | KMT2A (0.43) | KMT2AMAPTMEN1RAB9AALDH1A1 | |
| SCHEMBL6656855 | 0.94 | KMT2A (0.50) | KMT2AMAPTMEN1RAB9AALDH1A1 | |
| SCHEMBL6656545 | 0.91 | KMT2A (0.44) | KMT2AMAPTMEN1RAB9AALDH1A1 | |
| SCHEMBL6657243 | 0.91 | KMT2A (0.45) | KMT2AMAPTMEN1RAB9AALDH1A1 | |
| SCHEMBL6660678 | 0.90 | KMT2A (0.43) | KMT2AMAPTMEN1RAB9AALDH1A1 | |
| SCHEMBL6661542 | 0.89 | KMT2A (0.44) | KMT2AMAPTMEN1RAB9AALDH1A1 | |
| SCHEMBL6656273 | 0.89 | KMT2A (0.45) | KMT2AMAPTMEN1RAB9AALDH1A1 | |
| SCHEMBL6653511 | 0.89 | KMT2A (0.52) | KMT2AMAPTMEN1RAB9AALDH1A1 | |
| SCHEMBL6656885 | 0.89 | KMT2A (0.43) | KMT2AMAPTMEN1RAB9AALDH1A1 | |
| SCHEMBL6685841 | 0.88 | LMNA (0.44) | KMT2AMAPTMEN1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2004-11-25 | — | — | US | disclosed |
| EP-1438283-A1 | DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | NOVO NORDISK A/S (DK) | 2004-07-21 | — | — | EP | disclosed |
| EP-1435958-A1 | USE OF PHOSPHORODIESTERASE IV INHIBITORS | MERCK PATENT GmbH (DE) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003033453-A1 | DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003032993-A1 | USE OF PHOSPHORODIESTERASE IV INHIBITORS | MERCK PATENT GMBH (DE) | 2003-04-24 | — | — | WO | disclosed |
| EP-0763534-B1 | Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GMBH (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-5859008-A | Arylalkyl diazinones | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-01-12 | — | — | US | disclosed |
| EP-0763534-A1 | Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors | MERCK PATENT GmbH (DE) | 1997-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235845-A1 | Use of phosphodiesterase iv inhibitors | PDE4A, PDE3A, PDE3B | KMT2A 3056/4885MAPT 3595/4885MEN1 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.